Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|12|3|237-246

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.12, Iss.3, 2012-03, pp. : 237-246

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-01 ,pp. : 1263-1272

Bentham Science Publishers

Access to resources Recommend Favorite

Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer

By  

Current Cancer Drug Targets, Vol. 15, Iss. 9, 2015-11 ,pp. : 792-802

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

By  

Current Medicinal Chemistry, Vol. 19, Iss. 20, 2012-07 ,pp. : 3337-3352

Bentham Science Publishers

Access to resources Recommend Favorite

The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer

By Gridelli Cesare   Rossi Antonio   Bareschino Maria Anna   Schettino Clorinda   Sacco Paola Claudia   Maione Paolo  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 5, 2010-05 ,pp. : 631-639

Informa Healthcare

Access to resources Recommend Favorite

Role of Genotyping in Non-Small Cell Lung Cancer Treatment: Current Status

By Bonanno Laura   Favaretto Adolfo   Rugge Massimo   Taron Miquel   Rosell Rafael  

Drugs, Vol. 71, Iss. 17, 2011-12 ,pp. : 2231-2246

Adis International

Access to resources Recommend Favorite